SNH-119014 study for non-transfusion-dependent thalassemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new medication called SNH-119014 to treat a type of thalassemia (an inherited blood disorder) in adults who don't regularly need blood transfusions. The goal is to see if this drug can improve your hemoglobin levels and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with non-transfusion-dependent thalassemia (not the sickle cell form)
- Your hemoglobin level is 10.0 grams per deciliter or lower
- You have not had a heart attack, stroke, blood clot, or heart failure in the past 6 months
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
This trial tests an oral medication called AND017 for people with beta-thalassemia. It aims to see if the drug can safely help reduce the need for blood transfusions or improve hemoglobin levels.
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
This study tests whether a combination of two drugs, luspatercept and thalidomide, can help people with beta-thalassemia who need regular blood transfusions. It aims to reduce the number of transfusions needed.
This trial tests a new drug called SNH-119014 for the first time in humans. It involves healthy volunteers to check the drug's safety and how the body processes it. It may be a step toward a new treatment for certain conditions.
Hear when a new Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.